
At least six brokerages start coverage on medical supplies maker and distributor Medline MDLN.O with bullish ratings as industry-mandated quiet period ends
Medline made its public-market debut in December, valuing co at $46 billion in the largest U.S. IPO since Rivian's RIVN.O 2021 listing
JPM says MDLN’s recent market share gains are likely to endure, with co well-placed to keep winning business by offering cost savings alongside strong service
Jefferies says co is expected to grow at high single‑digit pace or better, with growth split evenly between existing customers and new client wins
Trading price of $40.52 as of Friday's close is higher than IPO price of $29
Ratings and PTs on the stock:
Brokerage | Rating | PT |
J.P. Morgan | Overweight | $50 |
Leerink Partners | Outperform | $48 |
Baird | Outperform | $48 |
RBC | Outperform | $47 |
Piper Sandler | Overweight | $50 |
Jefferies | Buy | $50 |